Wayne Wilson has been elected to the board of directors of ARIAD Pharmaceuticals, which is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules.
ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development.
Return to Top